The gene therapy developer has followed a $120m round co-led by Novo three weeks ago by filing to go public on the Nasdaq Global Select Market.
UK-based gene therapy developer Freeline Therapeutics has filed for a $100m initial public offering in the United States that will give pharmaceutical firm Novo the chance to exit.
Freeline is developing adeno-associated virus (AAV) gene therapies, and the AAVS3 virus that forms the basis of its drug candidates was developed at University College London by a team led by co-founder Amit Nathwani.
The IPO proceeds will be used to take a product candidate known as FLT180a through the completion…
